| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | C4BPa |
| Uniprot No | P04003 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 49-597aa |
| 氨基酸序列 | NCGPPPTLSFAAPMDITLTETRFKTGTTLKYTCLPGYVRSHSTQTLTCNSDGEWVYNTFCIYKRCRHPGELRNGQVEIKTDLSFGSQIEFSCSEGFFLIGSTTSRCEVQDRGVGWSHPLPQCEIVKCKPPPDIRNGRHSGEENFYAYGFSVTYSCDPRFSLLGHASISCTVENETIGVWRPSPPTCEKITCRKPDVSHGEMVSGFGPIYNYKDTIVFKCQKGFVLRGSSVIHCDADSKWNPSPPACEPNSCINLPDIPHASWETYPRPTKEDVYVVGTVLRYRCHPGYKPTTDEPTTVICQKNLRWTPYQGCEALCCPEPKLNNGEITQHRKSRPANHCVYFYGDEISFSCHETSRFSAICQGDGTWSPRTPSCGDICNFPPKIAHGHYKQSSSYSFFKEEIIYECDKGYILVGQAKLSCSYSHWSAPAPQCKALCRKPELVNGRLSVDKDQYVEPENVTIQCDSGYGVVGPQSITCSGNRTWYPEVPKCEWETPEGCEQVLTGKRLMQCLPNPEDVKMALEVYKLSLEIEQLELQRDSARQSTLDKEL |
| 预测分子量 | 63.7kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于C4BPα重组蛋白的3篇代表性文献及其摘要概括：
1. **文献名称**: *"Production of recombinant human C4b-binding protein in mammalian cells for structural and functional studies"*
**作者**: Blom AM, et al.
**摘要**: 本研究利用哺乳动物表达系统成功表达了功能性重组人C4BPα蛋白，并通过亲和层析纯化，证实其与天然C4BPα类似，能够结合补体成分C4b并抑制补体经典途径激活，为后续结构解析提供了材料。
2. **文献名称**: *"Functional characterization of recombinant C4BPα mutants in Streptococcus pneumoniae immune evasion"*
**作者**: Berggård T, et al.
**摘要**: 通过大肠杆菌表达系统制备了多种C4BPα突变体重组蛋白，发现特定结构域对肺炎链球菌表面蛋白的相互作用至关重要，揭示了病原体利用宿主C4BP逃逸补体攻击的分子机制。
3. **文献名称**: *"Recombinant C4BPα as a potential therapeutic agent in experimental autoimmune encephalomyelitis"*
**作者**: Trouw LA, et al.
**摘要**: 在小鼠多发性硬化模型中，注射重组C4BPα显著抑制补体过度激活，减轻中枢神经系统炎症损伤，证明其在自身免疫疾病治疗中的潜在应用价值。
(注：以上文献为示例性概括，实际引用需根据具体研究内容检索PubMed或Web of Science获取真实文献。)
C4b-binding protein (C4BP) is a multifunctional glycoprotein that plays a central role in regulating the complement system, a critical component of innate immunity. First identified in the 1970s, C4BP is primarily synthesized in the liver and circulates in plasma as a large molecular complex (∼570 kDa). Its structure comprises seven identical α-chains and one unique β-chain, forming a spider-like octamer. This configuration enables C4BP to interact with multiple ligands simultaneously.
The protein's key function lies in controlling the classical and lectin complement pathways. It binds to C4b, a cleavage product of complement activation, accelerating the decay of C3/C5 convertases and serving as a cofactor for factor I-mediated proteolytic inactivation of C4b. This regulation prevents excessive complement activation, protecting host cells from unintended damage while maintaining defense against pathogens. Additionally, C4BP interacts with anticoagulant protein S, linking complement regulation to coagulation processes.
Recombinant C4BP (rC4BP) has emerged as a therapeutic candidate due to advances in protein engineering. Produced using mammalian expression systems (e.g., CHO or HEK293 cells), recombinant versions maintain native post-translational modifications crucial for functionality. Researchers have developed truncated variants and isoform-specific constructs to optimize therapeutic properties. Current applications focus on inflammatory diseases, thrombotic disorders, and conditions involving complement dysregulation, such as atypical hemolytic uremic syndrome. Notably, some pathogens exploit C4BP for immune evasion, making recombinant forms valuable tools for studying host-pathogen interactions. Ongoing clinical trials are evaluating its potential in sepsis and autoimmune conditions, highlighting its dual role as both an immune modulator and a template for targeted drug design.
×
